Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NYR-BI03 in Healthy Volunteers
NCT06894862Phase 1Completed
- Sponsor
- Nyrada Inc
- Start
- Mar 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in stroke, traumatic brain injury (TBI) and myocardial infarction (MI) comparing NYR-BI03 with Placebo (2 arms). Primary endpoint: Number of Participants with Treatment-Related Adverse Events at Day 7. Started Mar 2025; status: completed.
02
Drugs
Xolatryp
03
Conditions
stroketraumatic brain injury (TBI)myocardial infarction (MI)
Beyond the preview
Go deeper on NCT06894862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06894862.